AR054371A1 - Metodos y composiciones para manejo de desordenes psicoticos - Google Patents

Metodos y composiciones para manejo de desordenes psicoticos

Info

Publication number
AR054371A1
AR054371A1 ARP060102273A ARP060102273A AR054371A1 AR 054371 A1 AR054371 A1 AR 054371A1 AR P060102273 A ARP060102273 A AR P060102273A AR P060102273 A ARP060102273 A AR P060102273A AR 054371 A1 AR054371 A1 AR 054371A1
Authority
AR
Argentina
Prior art keywords
ingredient
psychotic
psychotic disorders
compositions
methods
Prior art date
Application number
ARP060102273A
Other languages
English (en)
Inventor
Gary Tollefdon
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37091795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054371(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of AR054371A1 publication Critical patent/AR054371A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las composiciones para el tratamiento de desordenes psicoticos comprenden un primer ingrediente y un segundo ingrediente, caracterizados porque el primer ingrediente comprende al menos un agente anti-psicotico seleccionado del grupo consistente de ziprasidona, olanzapina y risperidona, y el segundo ingrediente compende al menos un anticonvulsivo seleccionado del grupo consistente de zonisamida y topiramato. Los métodos para tratar desordenes psicoticos, síntomas asociados con desordenes psicoticos y efectos colaterales asociados con agentes anti-psicoticos, comprenden la administracion de un primer ingrediente y un segundo ingrediente, caracterizados porque el primer ingrediente comprende al menos un agente anti-psicotico seleccionado del grupo consistente de ziprasidona, olanzapina y risperidona, y el segundo ingrediente compende al menos un anticonvulsivo seleccionado del grupo consistente de zonisamida y topiramato. El segundo ingrediente de las composiciones y métodos puede comprender adicionalmente un antidepresivo. En varias presentaciones, el agente anti-psicotico y el anticonvulsivo actuan de manera sinérgica para aliviar los síntomas y/o efectos colaterales asociados con los desordenes psicoticos y su tratamiento.
ARP060102273A 2005-05-31 2006-05-31 Metodos y composiciones para manejo de desordenes psicoticos AR054371A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68612805P 2005-05-31 2005-05-31

Publications (1)

Publication Number Publication Date
AR054371A1 true AR054371A1 (es) 2007-06-20

Family

ID=37091795

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102273A AR054371A1 (es) 2005-05-31 2006-05-31 Metodos y composiciones para manejo de desordenes psicoticos

Country Status (14)

Country Link
US (1) US20060276412A1 (es)
EP (1) EP1890700A2 (es)
JP (1) JP2008542378A (es)
KR (1) KR20080021046A (es)
CN (1) CN101208092A (es)
AR (1) AR054371A1 (es)
AU (1) AU2006252708A1 (es)
BR (1) BRPI0611322A2 (es)
CA (1) CA2609193A1 (es)
IL (1) IL187473A0 (es)
MX (1) MX2007015052A (es)
RU (1) RU2007142346A (es)
TW (1) TW200716139A (es)
WO (1) WO2006130522A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316456B1 (en) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
EP1734955A2 (en) * 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007084290A2 (en) * 2006-01-12 2007-07-26 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
TW201811315A (zh) 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
US9044471B2 (en) * 2007-02-01 2015-06-02 Alan I. Green Combinations of dopamine D2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
CA2712075A1 (en) 2008-01-17 2009-07-23 Suregene Llc Genetic markers of mental illness
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
WO2009120390A2 (en) * 2008-03-27 2009-10-01 Seton Hall University Cyclopropanated carbohydrates
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
WO2010002972A1 (en) 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
BRPI1007378A2 (pt) 2009-01-06 2020-08-18 Curemark Llc composições e métodos para o tratamento ou prevenção de infecções por staphylococcus aureus e para a erradicação ou redução de staphylococcus aureus sobre superfícies.
EP2947100B1 (en) 2009-01-06 2019-05-08 Galenagen, LLC Oral compositions for the treatment or the prevention of infections by E. Coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
AU2011270701B2 (en) * 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
HUE050873T2 (hu) * 2011-04-21 2021-01-28 Curemark Llc Vegyületek neuropszichiátriai rendellenességek kezelésére
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP4104824A1 (en) 2012-06-06 2022-12-21 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
EP2900270B1 (en) 2012-09-26 2019-03-06 Tangent Reprofiling Limited Combination of benzo(iso)oxazolepiperidines with conjugated linoleic acid
US10154988B2 (en) * 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
WO2016191316A1 (en) * 2015-05-22 2016-12-01 Stem Cell Theranostics, Inc. Modulation of drug-induced cardiotoxicity
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
CA2445528A1 (en) * 2001-04-26 2002-11-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
US7109198B2 (en) * 2002-05-17 2006-09-19 Duke University Method for treating obesity
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
EP1734955A2 (en) * 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
US20060058293A1 (en) * 2004-08-03 2006-03-16 Eckard Weber Combination of bupropion and a second compound for affecting weight loss
US20060246131A1 (en) * 2005-04-28 2006-11-02 Cottlingham Elizabeth M Use of metformin to counteract weight gain associated with psychotropic medications

Also Published As

Publication number Publication date
IL187473A0 (en) 2008-03-20
EP1890700A2 (en) 2008-02-27
MX2007015052A (es) 2008-01-18
AU2006252708A1 (en) 2006-12-07
RU2007142346A (ru) 2009-07-20
JP2008542378A (ja) 2008-11-27
WO2006130522A2 (en) 2006-12-07
TW200716139A (en) 2007-05-01
BRPI0611322A2 (pt) 2010-08-31
CA2609193A1 (en) 2006-12-07
US20060276412A1 (en) 2006-12-07
KR20080021046A (ko) 2008-03-06
CN101208092A (zh) 2008-06-25
WO2006130522A3 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
AR054371A1 (es) Metodos y composiciones para manejo de desordenes psicoticos
AR051968A1 (es) Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
DOP2006000252A (es) Profarmacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y metodos
SV2008003071A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
AR051969A1 (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
BR112013000027A2 (pt) tratamento de distúrbios cognitivos
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
NO20081628L (no) Benzodiazepiner som HCV-inhibitorer
EA200800337A1 (ru) Композиция и способ введения офтальмологически активных средств
CL2022003733A1 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CL2007002671A1 (es) Compuestos derivados de octahidro-pirrolo[3,4-c]pirrol; composicion farmaceutica que la comprende; y uso del compuesto en el tratamiento del vih, sida o arc.
AR062658A1 (es) Terapias de combinacion para artritis reumatoide
DOP2023000037A (es) Compuestos fosfolípidos y usos de los mismos
BRPI0519355A2 (pt) compostos para tratamento contra flaviviridae
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
BRPI0519621A2 (pt) usos de sabcomelina, de uma composiÇço farmacÊutica, de pelo menos um agente antimanÍaco ou estabilizador do humor, e de uma combinaÇço de sabcomelina ou um sal farmaceuticamente aceitÁvel da mesma e pelo menos um agente antimanÍaco ou estabilizador do humor, composiÇço farmacÊutica, kit de partes para uso no tratamento de distérbios bipolares, sabcomelina, e, mÉtodo de tratamento de distérbios biopolares
PA8597501A1 (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure